DDR1 Protein Linked to Poor Pancreatic Cancer Outcomes
Researchers found that targeting this protein may help sensitize pancreatic tumors to ferroptosis-based treatments.
Updated on Sept. 23, 2026 in Cancer
High levels of the protein DDR1 have been linked to poorer prognoses in patients with pancreatic ductal adenocarcinoma. A new study suggests that inhibiting this protein could improve the effectiveness of therapeutic strategies that induce cancer cell death through ferroptosis.
Why it matters
Pancreatic ductal adenocarcinoma remains difficult to treat, and this finding identifies a specific molecular pathway that helps cancer cells evade programmed cell death. Understanding how to disrupt this resistance mechanism could lead to more effective future treatment combinations.
In a preclinical study, researchers observed that DDR1 overexpression suppresses ferroptosis in pancreatic cancer cells. Inhibiting DDR1 with Dasatinib was shown to sensitize these cells to DHA-induced cell death, as evidenced by increased 4-HNE accumulation.
The players
Dasatinib
A targeted kinase inhibitor medication that works to block specific proteins involved in cancer cell growth.
The details
The DDR1 protein acts as a signal transducer, recruiting SHC1 to activate the MAPK/ERK pathway. This activation drives the production of SLC40A1, an iron exporter that depletes intracellular iron levels, which the cancer cells use to resist ferroptosis—a type of iron-dependent cell death. By inhibiting DDR1, scientists were able to reverse this protection, leading to increased markers of cellular stress and tumor growth inhibition.
Timeline
September 23, 2026: Findings were published regarding the role of DDR1 in pancreatic ductal adenocarcinoma.
Health Landscape
This research contributes to the growing effort to overcome resistance in pancreatic ductal adenocarcinoma, which has historically been resistant to many conventional therapies. It sits within the broader evolution of cancer science moving toward ferroptosis-based strategies to trigger cell death.
These findings are strictly preclinical and do not currently change clinical practice or treatment guidelines. Patients managing a pancreatic cancer diagnosis should consult their oncologist about the most appropriate evidence-based clinical trials for their specific tumor profile.
The takeaway
DDR1 protein expression functions as a protective mechanism that helps pancreatic cancer cells avoid natural cell death. Research into ferroptosis-inducing treatments is a space to watch as scientists work to develop strategies that can effectively overcome this tumor resistance.
Further reading
For more on evolving research in this field, explore the latest updates in Cancer.
Source note: This article includes information reported by Nature.
